Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study)
Authors' conclusion
In real-world clinical practice, the combination of SGLT2i and GLP-1 RA may be more effective for preserving kidney function than GLP-1 RA monotherapy. This effect was not seen with combination versus SGLT2i monotherapy.
Study context
- Population
- People with T2D prescribed SGLT2is and/or GLP-1 RAs, January 2013–December 2021, Oxford-Royal College of General Practitioners Research and Surveillance Centre primary care sentinel networktwo matched cohorts
- Exposure
- SGLT2i plus GLP-1 RA combination vs monotherapy
- Outcome
- Adjusted mean difference in absolute change in eGFR
- Follow-up
- baseline to 1- and 2-years follow-up
Methodological detailsprevalent new-user design, 1:1 propensity score matched
- Prevalent new-user design
- 1:1 propensity score matched
Main finding
As reported in the abstract
Change in eGFR, combination vs GLP-1 RA monotherapy (matched N = 14 154) · 1 and 2 years
Combination vs GLP-1 RA monotherapyMean difference (95% CI)P value
At 1-year; smaller eGFR reduction with combination
2.2(1.7–2.8)
P < 0.001At 2-years
2.1(1.4–2.7)
P < 0.001mL/min/1.73 m²
- Mean decline in estimated glomerular filtration rate (eGFR) across matched groups, baseline to 1-year
- −5.4
- Mean decline in eGFR across matched groups, baseline to 2-years
- −6.1
Observational data: associations, not effects.
Further findings
Change in eGFR, combination vs SGLT2i monotherapy (matched N = 14 774) · 1 and 2 years
mL/min/1.73 m²
- Mean decline in eGFR across matched groups, baseline to 1-year
- −4.5
- Mean decline in eGFR across matched groups, baseline to 2-years
- −5.0
- No difference between combination and SGLT2i monotherapy
- Propensity score matched
Original publication
Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice ( CombiKid Study). Diabetes Obes Metab. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →